Innate Pharma SA (IPHYF) Ratios
Innate Pharma SA Ratios
IPHYF's free cash flow for Q2 2026 was $-21.13M. For the 2026 fiscal year, IPHYF's free cash flow was decreased by $-90.00K and operating cash flow was $-21.04M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 |
| Quick Ratio | 1.27 | 2.60 | 3.73 | 3.38 | 1.73 |
| Cash Ratio | 0.77 | 2.01 | 1.78 | 2.04 | 1.30 |
| Solvency Ratio | -0.57 | -0.46 | -0.02 | -0.35 | -0.30 |
| Operating Cash Flow Ratio | -1.44 | -0.21 | -0.82 | -0.46 | -0.73 |
| Short-Term Operating Cash Flow Coverage | -6.20 | -0.79 | -3.85 | -15.17 | -1.95 |
| Net Current Asset Value | $ -37.71M | $ -16.48M | $ 15.72M | $ -13.88M | $ -21.80M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.36 | 0.28 | 0.22 | 0.20 | 0.17 |
| Debt-to-Equity Ratio | -1.04 | 3.55 | 0.77 | 0.78 | 0.41 |
| Debt-to-Capital Ratio | 25.98 | 0.78 | 0.43 | 0.44 | 0.29 |
| Long-Term Debt-to-Capital Ratio | -1.70 | 0.72 | 0.37 | 0.42 | 0.10 |
| Financial Leverage Ratio | -2.89 | 12.57 | 3.55 | 3.84 | 2.49 |
| Debt Service Coverage Ratio | -4.28 | -3.43 | -0.20 | -39.52 | -1.43 |
| Interest Coverage Ratio | -18.38 | -12.97 | -19.80 | -85.52 | -153.29 |
| Debt to Market Cap | 0.16 | 0.26 | 0.24 | 0.20 | 0.15 |
| Interest Debt Per Share | 0.29 | 0.58 | 0.67 | 0.70 | 0.73 |
| Net Debt to EBITDA | 0.10 | 0.69 | 16.70 | 0.68 | 1.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | -252.41% | 10.83% | 12.11% | -288.08% |
| EBIT Margin | -2058.02% | -419.77% | -13.35% | -132.39% | -394.86% |
| EBITDA Margin | -2008.36% | -403.98% | -3.54% | -123.48% | -356.91% |
| Operating Profit Margin | -2058.02% | -408.61% | -24.41% | -49.62% | -394.86% |
| Pretax Profit Margin | -1987.15% | -451.27% | -14.59% | -116.79% | -375.48% |
| Net Profit Margin | -1764.51% | -391.94% | -14.59% | -117.05% | -436.01% |
| Continuous Operations Profit Margin | -1764.51% | -391.94% | -14.59% | -116.79% | -375.48% |
| Net Income Per EBT | 88.80% | 86.85% | 100.00% | 100.23% | 116.12% |
| EBT Per EBIT | 96.56% | 110.44% | 59.75% | 235.38% | 95.09% |
| Return on Assets (ROA) | -78.41% | -44.54% | -4.11% | -27.95% | -19.74% |
| Return on Equity (ROE) | 226.58% | -560.01% | -14.59% | -107.30% | -49.15% |
| Return on Capital Employed (ROCE) | -220.01% | -66.06% | -8.76% | -14.79% | -25.49% |
| Return on Invested Capital (ROIC) | -146.05% | -51.45% | -8.25% | -14.61% | -21.90% |
| Return on Tangible Assets | -78.41% | -44.54% | -4.12% | -28.16% | -23.65% |
| Earnings Yield | -34.37% | -42.07% | -4.74% | -28.99% | -19.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.37 | 2.54 | 1.12 | 1.60 | 0.90 |
| Payables Turnover | 0.00 | 3.25 | 6.54 | 3.78 | 3.19 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.64 | 2.46 | 8.21 | 5.81 | 1.19 |
| Asset Turnover | 0.04 | 0.11 | 0.28 | 0.24 | 0.05 |
| Working Capital Turnover Ratio | 0.09 | 0.16 | 0.50 | 0.63 | 0.13 |
| Cash Conversion Cycle | 996.65 | 31.38 | 271.16 | 131.61 | 291.64 |
| Days of Sales Outstanding | 996.65 | 143.78 | 326.94 | 228.09 | 406.01 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 112.40 | 55.78 | 96.48 | 114.38 |
| Operating Cycle | 996.65 | 143.78 | 326.94 | 228.09 | 406.01 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.59 | -0.11 | -0.53 | -0.31 | -0.96 |
| Free Cash Flow Per Share | -0.59 | -0.12 | -0.57 | -0.33 | -0.98 |
| Dividend Paid and CapEx Coverage Ratio | -376.82 | -17.64 | -13.85 | -17.07 | -43.95 |
| Capital Expenditure Coverage Ratio | -376.82 | -17.64 | -13.85 | -17.07 | -43.95 |
| Operating Cash Flow Coverage Ratio | -2.34 | -0.22 | -0.82 | -0.45 | -1.32 |
| Operating Cash Flow to Sales Ratio | -18.93 | -0.55 | -0.63 | -0.39 | -4.83 |
| Free Cash Flow Yield | -36.97% | -6.20% | -21.87% | -10.12% | -22.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.91 | -3.16 | -21.09 | -3.45 | -5.13 |
| Price-to-Sales (P/S) Ratio | 51.33 | 9.32 | 3.08 | 4.04 | 22.37 |
| Price-to-Book (P/B) Ratio | -6.59 | 13.31 | 3.08 | 3.70 | 2.52 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.70 | -16.14 | -4.57 | -9.89 | -4.53 |
| Price-to-Operating Cash Flow Ratio | -2.71 | -17.05 | -4.90 | -10.46 | -4.64 |
| Price-to-Earnings Growth (PEG) Ratio | 0.30 | -0.01 | 0.24 | 2.55 | 0.17 |
| Enterprise Value Multiple | -2.46 | -1.62 | -70.10 | -2.59 | -4.89 |
| Enterprise Value | 137.54M | 82.56M | 128.91M | 158.47M | 211.49M |
| EV to EBITDA | -2.46 | -1.62 | -70.10 | -2.59 | -4.89 |
| EV to Sales | 49.35 | 6.54 | 2.48 | 3.19 | 17.46 |
| EV to Free Cash Flow | -2.60 | -11.33 | -3.69 | -7.82 | -3.54 |
| EV to Operating Cash Flow | -2.61 | -11.97 | -3.96 | -8.27 | -3.62 |
| Tangible Book Value Per Share | -0.24 | 0.14 | 0.85 | 0.86 | 1.04 |
| Shareholders’ Equity Per Share | -0.24 | 0.14 | 0.85 | 0.89 | 1.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.11 | 0.13 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.21 | 0.85 | 0.81 | 0.20 |
| Net Income Per Share | -0.55 | -0.81 | -0.12 | -0.95 | -0.87 |
| Tax Burden | 0.89 | 0.87 | 1.00 | 1.00 | 1.16 |
| Interest Burden | 0.97 | 1.08 | 1.09 | 0.88 | 0.95 |
| Research & Development to Revenue | 15.65 | 4.12 | 1.08 | 1.04 | 3.88 |
| SG&A to Revenue | 3.95 | 1.40 | 0.23 | 0.29 | 1.32 |
| Stock-Based Compensation to Revenue | 1.53 | 0.31 | 0.08 | 0.09 | 0.22 |
| Income Quality | 1.07 | 0.14 | 4.30 | 0.33 | 1.11 |
Currency in EUR